JP2006514012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514012A5 JP2006514012A5 JP2004555329A JP2004555329A JP2006514012A5 JP 2006514012 A5 JP2006514012 A5 JP 2006514012A5 JP 2004555329 A JP2004555329 A JP 2004555329A JP 2004555329 A JP2004555329 A JP 2004555329A JP 2006514012 A5 JP2006514012 A5 JP 2006514012A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- formula
- compound according
- acceptable salt
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42889302P | 2002-11-22 | 2002-11-22 | |
| PCT/US2003/032747 WO2004048382A1 (en) | 2002-11-22 | 2003-11-10 | Quinolinyl-pyrrolopyrazoles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006514012A JP2006514012A (ja) | 2006-04-27 |
| JP2006514012A5 true JP2006514012A5 (enExample) | 2006-12-14 |
| JP4542906B2 JP4542906B2 (ja) | 2010-09-15 |
Family
ID=32393478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004555329A Expired - Fee Related JP4542906B2 (ja) | 2002-11-22 | 2003-11-10 | キノリニル−ピロロピラゾール類 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7265225B2 (enExample) |
| EP (1) | EP1565471B1 (enExample) |
| JP (1) | JP4542906B2 (enExample) |
| KR (1) | KR101057282B1 (enExample) |
| CN (1) | CN100345852C (enExample) |
| AT (1) | ATE341550T1 (enExample) |
| AU (1) | AU2003291643B2 (enExample) |
| BR (1) | BR0315337A (enExample) |
| CA (1) | CA2501322C (enExample) |
| CO (1) | CO5570677A2 (enExample) |
| CR (1) | CR7830A (enExample) |
| CY (1) | CY1106283T1 (enExample) |
| DE (1) | DE60308893T2 (enExample) |
| DK (1) | DK1565471T3 (enExample) |
| EA (1) | EA008387B1 (enExample) |
| EC (1) | ECSP055807A (enExample) |
| EG (1) | EG25822A (enExample) |
| ES (1) | ES2273046T3 (enExample) |
| HR (1) | HRP20050436B1 (enExample) |
| IL (1) | IL168190A (enExample) |
| MX (1) | MXPA05005432A (enExample) |
| NO (1) | NO331403B1 (enExample) |
| NZ (1) | NZ538942A (enExample) |
| PL (1) | PL227840B1 (enExample) |
| PT (1) | PT1565471E (enExample) |
| UA (1) | UA80571C2 (enExample) |
| WO (1) | WO2004048382A1 (enExample) |
| ZA (1) | ZA200503121B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2004050659A1 (en) * | 2002-11-27 | 2004-06-17 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
| EP1910370B1 (en) | 2005-07-22 | 2015-04-22 | Eli Lilly And Company | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
| WO2007039151A1 (en) * | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| PL2918288T3 (pl) | 2006-10-03 | 2018-02-28 | Genzyme Corporation | Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej |
| EP2527345B1 (en) * | 2006-10-16 | 2015-12-16 | Thesan Pharmaceuticals, Inc. | Therapeutic pyrazolyl thienopyridines |
| SG186821A1 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| SG194512A1 (en) | 2011-04-21 | 2013-12-30 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
| CA2853484C (en) | 2011-10-26 | 2018-08-21 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| WO2013078286A1 (en) | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| CN105121418A (zh) | 2012-04-20 | 2015-12-02 | 吉利德科学公司 | 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途 |
| EP3685855B1 (en) | 2012-10-05 | 2023-11-22 | Kadmon Corporation, LLC | Human anti-vegfr-2/kdr antibodies |
| EP2917365B1 (en) | 2012-11-12 | 2020-03-11 | Institució Catalana de Recerca i Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY |
| US10822337B2 (en) | 2015-04-01 | 2020-11-03 | Rigel Pharmaceuticals, Inc. | TGF-β inhibitorC |
| JP6856648B2 (ja) | 2015-12-15 | 2021-04-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｘｃｒ４受容体アンタゴニスト |
| US10604528B2 (en) | 2016-07-07 | 2020-03-31 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Galunisertib crystalline form, preparation method thereof and use thereof |
| WO2018165979A1 (zh) * | 2017-03-17 | 2018-09-20 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物 |
| CN110582279B (zh) * | 2017-03-21 | 2023-07-14 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 |
| WO2019042383A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019105082A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019137027A1 (zh) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| EP3827010B1 (en) | 2018-07-23 | 2025-08-27 | Brise Pharmaceuticals Co., Ltd. | Bisphosphonate drug conjugates |
| MX2021007738A (es) | 2018-12-27 | 2021-08-05 | Nexys Therapeutics Inc | Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer. |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020248908A1 (zh) * | 2019-06-10 | 2020-12-17 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
| US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| CN115243724B (zh) | 2020-02-19 | 2025-10-21 | 纳米医疗有限公司 | 可用于治疗癌症的经调配和/或共调配的含有TFGβ拮抗剂前药的脂质体组合物和其方法 |
| CN121712526A (zh) | 2023-06-13 | 2026-03-20 | 辛瑟斯治疗股份有限公司 | 抗cd5抗体及其用途 |
| GB202309553D0 (en) | 2023-06-24 | 2023-08-09 | Ucl Business Ltd | Compostions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| EP1206474B1 (en) * | 1999-08-27 | 2004-05-26 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| SK287857B6 (sk) * | 2001-05-24 | 2012-01-04 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
-
2003
- 2003-10-11 UA UAA200504767A patent/UA80571C2/uk unknown
- 2003-11-10 MX MXPA05005432A patent/MXPA05005432A/es active IP Right Grant
- 2003-11-10 BR BR0315337-1A patent/BR0315337A/pt not_active Application Discontinuation
- 2003-11-10 PT PT03768531T patent/PT1565471E/pt unknown
- 2003-11-10 KR KR1020057009199A patent/KR101057282B1/ko not_active Expired - Fee Related
- 2003-11-10 AT AT03768531T patent/ATE341550T1/de active
- 2003-11-10 DK DK03768531T patent/DK1565471T3/da active
- 2003-11-10 DE DE60308893T patent/DE60308893T2/de not_active Expired - Lifetime
- 2003-11-10 NZ NZ538942A patent/NZ538942A/en not_active IP Right Cessation
- 2003-11-10 EP EP03768531A patent/EP1565471B1/en not_active Expired - Lifetime
- 2003-11-10 US US10/531,237 patent/US7265225B2/en not_active Expired - Fee Related
- 2003-11-10 PL PL376797A patent/PL227840B1/pl unknown
- 2003-11-10 EA EA200500859A patent/EA008387B1/ru not_active IP Right Cessation
- 2003-11-10 CN CNB2003801038400A patent/CN100345852C/zh not_active Expired - Fee Related
- 2003-11-10 HR HRP20050436AA patent/HRP20050436B1/hr not_active IP Right Cessation
- 2003-11-10 CA CA2501322A patent/CA2501322C/en not_active Expired - Fee Related
- 2003-11-10 AU AU2003291643A patent/AU2003291643B2/en not_active Ceased
- 2003-11-10 ES ES03768531T patent/ES2273046T3/es not_active Expired - Lifetime
- 2003-11-10 JP JP2004555329A patent/JP4542906B2/ja not_active Expired - Fee Related
- 2003-11-10 WO PCT/US2003/032747 patent/WO2004048382A1/en not_active Ceased
-
2005
- 2005-04-18 ZA ZA200503121A patent/ZA200503121B/en unknown
- 2005-04-21 IL IL168190A patent/IL168190A/en active IP Right Grant
- 2005-05-06 CR CR7830A patent/CR7830A/es unknown
- 2005-05-18 CO CO05048136A patent/CO5570677A2/es active IP Right Grant
- 2005-05-18 EG EGNA2005000237 patent/EG25822A/xx active
- 2005-05-19 EC EC2005005807A patent/ECSP055807A/es unknown
- 2005-06-21 NO NO20053045A patent/NO331403B1/no not_active IP Right Cessation
-
2006
- 2006-12-08 CY CY20061101769T patent/CY1106283T1/el unknown
-
2007
- 2007-07-25 US US11/782,659 patent/US7834029B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514012A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2021191784A5 (enExample) | ||
| JP2005518413A5 (enExample) | ||
| JP2007522220A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2006526031A5 (enExample) | ||
| CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
| JP2019524883A5 (enExample) | ||
| JP2005508905A5 (enExample) | ||
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| HRP20120803T1 (hr) | Prolijekovi alkilatora fosforamidata | |
| JP2008535902A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| CY1110631T1 (el) | Διαλυτοποιημενα δηλητηρια τοποϊσομερασης | |
| JP2003503449A5 (enExample) | ||
| CA2501322A1 (en) | Quinolinyl-pyrrolopyrazoles | |
| JP2005536503A5 (enExample) | ||
| JP2015500885A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| JP2009520695A5 (enExample) | ||
| JP2008511597A5 (enExample) | ||
| JP2019151627A5 (enExample) |